...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.
【24h】

Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.

机译：免疫组织化学分析C / EBPalpha非小细胞肺癌显示频繁在II期和iii a下调肿瘤:E3590的相关研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: We sought to determine the association of C/EBPalpha expression status with clinical, pathologic and molecular characteristics, as well as outcomes, in non-small-cell lung cancer (NSCLC). This is the first comprehensive study of this transcription factor in patients with NSCLC. PATIENTS AND METHODS: Our cohort originated from ECOG 3590 (randomized trial of postoperative adjuvant therapy with thoracic radiation or cisplatin and etoposide plus thoracic radiation in patients with completely resected stages II and IIIA NSCLC; and its laboratory correlate, ECOG 4592). One hundred and sixty four tumor samples contained sufficient material for immunohistochemical (IHC) analysis. C/EBPalpha tumor staining was compared to that of basal bronchial cells (3+). 0 or 1+ (weak) suggested lack of, while 2 or 3+ (strong) suggested C/EBPalpha expression. RESULTS: Ninety tumors (55%) had 0 or 1+ C/EBPalpha staining, and the remaining 74 (45%) 2 or 3+. Patients with squamous cell carcinomas had a higher percentage of weak C/EBPalpha IHC staining compared to other histologies (p=0.048) and there was a trend for loss of C/EBPalpha in poorly differentiated compared to well differentiated tumors (p=0.07). There was no association between C/EBPalpha IHC and mutations in p53 or K-ras. The median disease-free survival for patients with weak and strong C/EBPalpha IHC expression was 29.6 and 30.6 months, respectively (p=0.94). The median overall survival between the weak and strong groups was 43.5 and 38.5 months, respectively (p=0.83). CONCLUSIONS: Loss of expression of C/EBPalpha is seen in over half of stage II and IIIA NSCLC, specifically in squamous cell carcinomas and poorly differentiated tumors. Since down-regulation of C/EBPalpha is a common event in NSCLC, further elucidation of the involvement of C/EBPalpha in the pathogenesis and progression of lung cancer may identify novel therapeutic targets.
机译：目的:我们试图确定协会C / EBPalpha表达与临床状态,病理和分子特征结果在非小细胞肺癌(NSCLC)。转录因子在非小细胞肺癌患者。患者和方法:我们的队列源于ECOG 3590(术后的随机试验与胸辐射或辅助治疗顺铂和依托泊苷+胸辐射完全切除后患者的第二阶段和iii a非小细胞肺癌;ECOG 4592)。样本包含足够的材料免疫组织化学(包含IHC)分析。肿瘤染色比较基础支气管细胞(3 +)。缺乏,而2或3 +(强烈的)建议C / EBPalpha表达式。(55%)有0或1 + C / EBPalpha染色,和剩余的74(45%)2或3 +。鳞状细胞癌有较高的百分比疲弱的C / EBPalpha包含IHC染色比其他组织学(p = 0.048)和趋势失去C / EBPalpha分化不良分化良好的肿瘤相比(p = 0.07)。之间没有协会C / EBPalpha包含IHC和p53的突变或k。软弱和患者的无病生存是29.6和强大的C / EBPalpha包含IHC表达式分别为30.6个月(p = 0.94)。总体存活率之间的弱和强分别组织43.5和38.5个月(p = 0.83)。C / EBPalpha在二世和超过一半的阶段iii a非小细胞肺癌,特别是鳞状细胞癌及低分化肿瘤。由于下调C / EBPalpha是常见的在非小细胞肺癌,进一步的说明发病机理和C / EBPalpha的参与肺癌的进展可能识别小说治疗的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号